New York, NY, March 9 and Osaka, Japan, March 10, 2015 – Takeda Pharmaceutical Company Limited ("Takeda") today held a briefing for investors and analysts in New York, discussing the company’s gastroenterology (GI) therapeutic area.
Gastroenterology is one of Takeda’s core therapeutic areas. With a range of standard treatments and a turnover of ¥299bn (FY13), Takeda is a global leader in the field. The company presented its strategy to further expand, highlighting the global launch of Entyvio® (vedolizumab), the Japanese launch of Takecab (vonoprazan) and enhanced research and development activities.
Slides from today’s briefing and additional information about Takeda is available through its corporate website at http://www.takeda.com/investor-information/results/2014.html.